- The exploration of mechanisms of comorbidity between migraine and depression. [Review]
- JCJ Cell Mol Med 2019 May 20
- Migraine comorbid with depression is common and is often encountered in clinical practice. The comorbidity may lead to more serious conditions with other symptoms and a longer duration of treatment a…
Migraine comorbid with depression is common and is often encountered in clinical practice. The comorbidity may lead to more serious conditions with other symptoms and a longer duration of treatment and it may impose heavy economic and social burdens, directly or indirectly, on patients and their families. Numerous studies have been published on the association of migraine with depression. Numerous literature have showed that the comorbidity may have a common complicated pathogenic mechanism involving biopsychosocial characteristics, including abnormal brain development and shared genetic basis, as well as neurotransmitters, sex hormones and stress. In addition, some studies have identified the multiple, bidirectional relationship between migraine and depressive disorder. We searched the literature for the possible common mechanisms between migraine and depression and classified the research results.
- Migraines appear more likely to be caused by histamine rather than ethanol. [Journal Article]
- EJEur J Neurol 2019 May 20
- We read with interest the manuscript by Onderwater et al. that reported on alcoholic beverages as a trigger factor for migraines . Although, epidemiological studies have found a correlation betwee…
We read with interest the manuscript by Onderwater et al. that reported on alcoholic beverages as a trigger factor for migraines . Although, epidemiological studies have found a correlation between alcohol intake and headaches, a specific pathophysiologic mechanism of this headache remains unidentified . Particularly red wine was documented as the most common trigger for migraines in this evaluated population . Most commonly found biogenic amines in wine - histamine, tyramine, phenylethylamine, putrescine, cadaverine, spermidine, serotonin, tryptamine, agmatine - and, flavonoids have suspected relevance for migraines and this implies that ethanol seems not to be the main culprit for the headaches . This article is protected by copyright. All rights reserved.
- Reduced Short-Latency Afferent Inhibition Indicates Impaired Sensorimotor Integrity During Migraine Attacks. [Journal Article]
- HHeadache 2019 May 20
- CONCLUSIONS: Pronounced decrease in SAI during preictal and ictal periods in migraine was shown for the first time. Instead of inhibition to a conditioned stimulus, facilitation in the sensorimotor cortex was detected both ictally and preictally. Preictal SAI results suggest the presence of increased excitability state several hours prior to the headache phase. This phenomenon could be related to the cortical hyperresponsivity to sensory stimuli and cognitive disturbances accompanying migraine attacks as SAI is modulated by cholinergic activity.
- Patent Foramen Ovale: Pivotal Role of Transesophageal Echocardiography in the Indications for Closure, Assessment of Varying Anatomies and Post-procedure Follow-up. [Review]
- UMUltrasound Med Biol 2019 May 16
- Patent foramen ovale (PFO) is present in 15%-30% of the general population and has been associated with various pathologic states, including cryptogenic stroke, platypnea-orthodeoxia syndrome, decomp…
Patent foramen ovale (PFO) is present in 15%-30% of the general population and has been associated with various pathologic states, including cryptogenic stroke, platypnea-orthodeoxia syndrome, decompression sickness and migraine with auras. Transesophageal echocardiography (TEE) has a major role in the diagnostic evaluation of PFO, as well as in the post-procedural assessment after transcatheter closure. The goals of this article were to synthesize the echocardiographic transesophageal techniques required for accurate PFO diagnosis and careful anatomic assessment of its anatomic variants, to focus TEE indications for device closure as complementary to clinical indications and to assess the role of TEE in the post-procedure follow-up.
- Opioid free treatment algorithm for ED headache management: Effect on revisit rate. [Journal Article]
- AJAm J Emerg Med 2019 Apr 27
- CONCLUSIONS: Opioid use in the ED to treat patients with headaches or migraines may have several negative ramifications including increased risk of revisit, hospital admission, and increased ED length of stay.
- Comparing migraine with and without aura to healthy controls using RNA sequencing. [Journal Article]
- CCephalalgia 2019 May 19; :333102419851812
- CONCLUSIONS: We showed no clear distinct difference in gene expression profiles of peripheral blood of migraineurs and controls and were not able to replicate findings from previous studies. A larger sample size may be needed to detect minor differences.
- Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. [Journal Article]
- CCephalalgia 2019 May 19; :333102419847957
- CONCLUSIONS: Galcanezumab is consistently efficacious versus placebo in reducing monthly migraine headache days and several other key outcomes in patients with chronic migraine who have failed ≥2 or ≥1 preventives previously. In the subgroup with no prior failures, greater numerical differences were seen with galcanezumab, but statistical separation from placebo varied by dose and outcome.
- Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models. [Journal Article]
- CCephalalgia 2019 May 19; :333102419851810
- CONCLUSIONS: Both an agonist directed at the P2Y13 receptor and an antagonist of the P2X3 receptor seem to be viable potential anti-migraine therapies.
- Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. [Journal Article]
- CCephalalgia 2019 May 19; :333102419848122
- CONCLUSIONS: Our findings suggest that migraine without aura is not associated with macrophage-mediated inflammation specific to the head pain side.
New Search Next
- Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study. [Journal Article]
- DSDrug Saf 2019 May 17
- CONCLUSIONS: OnabotulinumtoxinA treatment was well tolerated over 108 weeks; no new safety signals were identified. The overall incidence of treatment-emergent adverse events and the most common individual events decreased with repeated onabotulinumtoxinA administration.